**Exploring the Relationship Between Bitter Gourd *(Momordica Charantia)* Consumption and Glycated Hemoglobin (HbA1c) in Type 2 Diabetes and Diabetic Hypertension Comorbidity**

**ABSTRACT**

**Aim:** The objective of this study was to examine the association between the frequency of bitter gourd consumption and HbA1c levels (Glycated Hemoglobin) among patients with T2DM and those with both T2DM and hypertension (T2DM\*HTN).

**Background:** In India, approximately 72.9 million individuals suffer from diabetes, and 317 million experience hypertension. Bitter gourd (*Momordica Charantia*) is traditionally used for the management of type 2 diabetes mellitus (T2DM). It is rich in nutrients and bioactive compounds like momordicin I, II and cucurbitacin B, which have antidiabetic effects. Its ability to regulate cholesterol, reduce fat accumulation, and improve antioxidant status supports cardiovascular and glycaemic health.

**Methodology:** A hospital-based, cross-sectional descriptive study was conducted with 320 patients aged 20 years and older, who were diagnosed with T2DM and/or hypertension. The frequency of bitter gourd consumption was assessed using a formative scale, and statistical analysis was performed using Fisher’s exact test and Somers’ *d* statistic to evaluate associations.

**Results:** Among the 320 patients, 31.3% had T2DM, 50.0% had HTN, and 19% showed co-prevalence of T2DM and HTN (T2DM\*HTN). The mean age of participants was 47.6 ± 1.07 years for T2DM and 54.5 ± 1.1 years for T2DM\*HTN. The mean HbA1c% levels were 8.6 ± 0.2% for T2DM and 8.2 ± 0.1% for T2DM\*HTN. The mean systolic and diastolic blood pressures for T2DM\*HTN patients were 136.5 ± 3.4 mmHg and 92.0 ± 2.6 mmHg, respectively. The study identified a modest but significant negative association between bitter gourd consumption and glycated hemoglobin levels (HbA1c) in patients with only diabetes (*p* < 0.05) suggests that frequent bitter gourd intake may contribute to a gradual reduction in glycemic levels. However, in diabetic hypertensive patients, no statistically significant association was observed (*p* > 0.05).

**Conclusion:** The findings indicate a potential role of bitter gourd in managing glycemic levels in T2DM, though further research is required to clarify its effects, particularly in patients with comorbid conditions.

*Keywords: Type 2 Diabetes Mellitus, Bitter gourd, Recommended Dietary Allowances, Gycated Hemoglobin, Blood Pressure*

**INTRODUCTION**

Cardiovascular diseases (CVDs), including coronary heart disease, stroke, and hypertension, are responsible for 31% of global deaths attributable to non-communicable diseases (NCDs), while diabetes accounts for 3% of such deaths. In India, CVDs and diabetes contributed to 27% and 3% of NCD-related deaths, respectively, in 2016 (WHO, 2018). Globally, an estimated 425 million adults are living with diabetes, of which 87%–91% have type 2 diabetes mellitus (T2DM). India ranks as the second most affected country, with approximately 72 million individuals diagnosed with diabetes (IDF, 2017). Additionally, 1.13 billion people worldwide have hypertension (defined as systolic blood pressure ≥140 mm Hg and diastolic blood pressure ≥90 mm Hg), including an estimated 317 million adults aged over 18 years in India in 2015 (WHO, 2018).

 According to the American Diabetes Association (ADA), hypertension is commonly associated with diabetes, with its prevalence influenced by the type and duration of diabetes mellitus, as well as factors such as age, sex, body mass index, and history of glycemic control (De Ferranti et al.,2014; Fox et al.,2015). Hypertension is a significant risk factor for both macrovascular and microvascular complications, making it a leading cause of morbidity and mortality in individuals with diabetes. It is also a major contributor to the direct and indirect healthcare costs associated with diabetes (De Boer et al., 2017). Diabetes increases the risk of CVDs, which worsens with coexistent hypertension due to shared mechanisms like oxidative stress, inflammation, and fibrosis. Managing hypertension and promoting vascular health may help reduce diabetes-related complications (Petrie & Touyz, 2018).

The World Health Organization (WHO) has identified an unhealthy diet as a modifiable risk factor significantly associated with the development of diabetes and hypertension (WHO, 2018). According to the Global Burden of Disease (GDB) study, poor nutrition is linked to approximately 11 million deaths worldwide, accounting for one in five global fatalities. Of these, CVDs were responsible for 9.13 lakh deaths, while type 2 diabetes contributed to 3.39 lakh deaths. These findings underscore the critical role of dietary interventions in mitigating the burden of these chronic conditions (GBD, 2017).

Furthermore, According to WHO data on chronic disease prevention, approximately 80% of diabetes- and hypertension-related events can be mitigated through the adoption of a balanced and nutritious diet. Key dietary measures include regular consumption of fruits and vegetables, limiting the intake of saturated fats, reducing sodium consumption, and minimizing the consumption of sugar-sweetened beverages. These dietary modifications play a crucial role in reducing the risk of these condition (NCD Risk Factor Collaboration, 2016; WHO, 2005).

 Bitter gourd is one of the traditional medicines which helps in the treatment of T2DM(Ahmad et al., 2016). Most scientific studies suggest that frequent consumption of bitter gourd can reduce several health-related problems either by its prophylactic or therapeutic effects(Anilakumar et al., 2015). It contains bitter chemicals such as charantin, vicine, glycosides and karavilosides along with polypeptide-plant insulin, which is hypoglycemic in nature and improves glycemic levels by rising glucose uptake and glycogen synthesis in the liver, muscles and fat cells(Gupta et al., 2011). Wehash et al (2012) observed that bitter melon seems to be exerting in decreasing capillary permeability compared to fenugreek extract. Generally, the increase in capillary permeability is a sign of microvascular dysfunction at the arteriolar and capillary level that is a common and critical complication of diabetes.

Furthermore, a review paper regarding medicinal properties of bitter melon and concluded that bitter melon might have properties that can help lower blood glucose level(Kwatra et al., 2016). Another systematic review and meta-analysis conducted by Yin et al (2014) in which he looked at four randomized controlled trials (RCTs) that compared the effects of bitter melon supplements with those of no diabetes treatment at all and concluded that no evidence that bitter melon had any significant effects on A1C levels or FBG level.

Moreover, Bitter melon extract has shown promise in managing hypertension when combined with dietary modifications and exercise. Some studies suggest it may reduce blood pressure by improving vascular function and inhibiting ACE activity(Dahlquist et al., 2023). Studies also suggest that peptides derived from bitter melon can inhibit angiotensin-converting enzyme (ACE), a critical enzyme in blood pressure regulation. This activity, combined with its antidiabetic effects, makes it potentially beneficial for individuals with metabolic syndrome, which often includes both diabetes and hypertension(Dahlquist et al., 2023; hung et al., 2024). A study using alloxan-induced diabetic albino rats demonstrated the hypoglycemic effects of *Momordica charantia* methanolic extract, showing a dose-dependent reduction in blood glucose levels. This provides scientific support for its potential use as a natural remedy for managing diabetes (kumar et al., 2024)

 Bitter melon (Momordica charantia) has demonstrated potential benefits for managing both type 2 diabetes mellitus (T2DM) and hypertension. Despite its observed benefits, no studies have specifically explored the relationship between bitter melon consumption, HbA1c levels, and the coexistence of diabetes and hypertension. Further research is needed to clarify these effects. Thus, present descriptive study aims to examine the connection between bitter melon consumption and HbA1c% in individuals with T2DM and comorbid diabetic hypertension.

**METHODOLOGY**

**Research Design and Participants**

This hospital-based cross-sectional study was conducted on patients with type 2 diabetes mellitus (T2DM) and hypertension (HTN) attending the outpatient clinics of the Endocrinology and General Medicine Departments at Jawaharlal Nehru Medical College and Hospital (JNMCH), Aligarh. Participants included male and female patients aged 20 years or older from diverse socioeconomic backgrounds residing in Aligarh city and who were regular visitors to JNMCH. Pregnant women and patients with severe illness were excluded from the analysis. This design ensured a representative sample of individuals with comorbid T2DM and HTN for analysis.

**Sampling Design**

On the basis of the earlier prevalence of the disease in Aligarh(NFHS, 2016), A calculated sample size of diabetes and hypertension were 160 and 110, by using the simplified sample size formula for proportions n = 4pq/ l2 with 5 % relative error respectively (Singh & Masuku, 2014). Quota sampling technique was used to select the sample. Furthermore, patients were stratified based on their disease situation such as patients with T2DM and HTN and T2DM\*HTN. During the study period of 6 months from August 2017 to January 2018, approximately 336 cases were identified. Out of which around 320 cases were selected for the final study. Moreover, nearly 60 cases of diabetic hypertensive (T2DM\*HTN) were extracted among the total sample (N = 320).

**Tools For Data Collection**

A valid and reliable (Cronbach's alpha = 0.896) self-prepared questionnaire cum interview schedule was designed to collect data regarding demographic information, anthropometric, clinical history, and detailed dietary habits from patients. A signed informed written consent was also taken. The height and weight were measured with the help of the standard stature meter (MCP Stature-meter04, manufactured by MCP, India) and digital platform weighing scale (Stand scale 7830.01.001 manufactured by Soehnle Backnang, Germany), respectively. BMI was calculated with the help of the equation proposed by Garrow and Webster (1985) (weight/height kg/m2) and categorized as per Indian adult standard(WHO, 2004; Indian Consensus Group, 1996).

**Nutritional Assessment**

A structured 24-hour diet recall method was employed over three consecutive days, including two weekdays and one holiday, allowing participants to recall their food and beverage consumption. Standardized weights and measures were used to ensure accurate quantification of food items in grams and liters. The nutrient content of the reported foods was analyzed using DietCal software 8.0, adapted to the Indian Food Composition Table(Longvah et al., 2017; Kaur, 2017). "During data collection, it was observed that some patients incorporated functional foods such as fenugreek, bitter gourd, and bottle gourd into their treatment regimens alongside prescribed medications. The frequency of their consumption was assessed using a formative scale and compared against the ICMR (2018) glycemic control guidelines for type 2 diabetes: HbA1c < 7% (ideal), HbA1c ≥ 7 and < 8% (satisfactory), and HbA1c ≥ 8% (unsatisfactory)”.

This analysis focused solely on patients with T2DM and T2DM\*HTN, as hypertensive patients without diabetes did not report using functional foods for managing blood pressure. Therefore, the evaluation of special food consumption (e.g., fenugreek seeds, bottle guard, bitter gourd) was limited to diabetic patients.

**Definitions:**

**Diabetes Mellitus**

Glycated hemoglobin (HbA1c) levels were used as a key outcome measure for assessing glycemic control in diabetic patients, obtained from their medical case records. Diabetes mellitus was diagnosed as per the criteria of WHO (2006) and ADA (2017)and recommendations as HbA1c ≥ 6.5%. Glycaemic control was categorized as per the recent guidelines provided by Indian Council of Medical Research (2018) for the management of type 2 diabetes mellitus (< 7 for ideal, ≥ 7 - < 8 for satisfactory and ≥ 8 for unsatisfactory glycaemic control). This categorization facilitated the evaluation of diabetes management among the study population.

**Hypertension**

Blood pressure was measured using a standardized sphygmomanometer (Model EHL DIAMOND-BPMR 120, manufactured by Diamond Pvt Ltd., India) employing the auscultation method. Hypertension was identified based on the use of prescribed antihypertensive medications or if blood pressure readings exceeded 140/90 mmHg, in accordance with JNC VIII criteria. The blood pressure goal for diabetic patients was defined as per the JNC VIII recommendations, with target levels set at < 140 mmHg for systolic blood pressure (SBP) and < 90 mmHg for diastolic blood pressure (DBP). This ensured the classification and management of hypertension aligned with the latest clinical guidelines(Paul et al., 2014).

**Statistical Analysis**

Data were analyzed using SPSS version 20.0 with both descriptive and inferential statistical methods. For the general features of patients, a univariate analysis in which mean and standard error of the mean was calculated for each metric variables and frequency and percentages were calculated for non-metric variables.

A non-parametric fisher exact test was applied to check the association between two non-metric categorical variables. Additionally, Somers’ *d* was computed as an index of effect size for nominal and ordinal data in Fisher’s exact test of association. This methodology provided a comprehensive analysis of the data, ensuring the robustness of findings.

**Results and Discussion**

As shown in Table 1, among the 320 samples, 31.3% of patients had T2DM, 50.0% had HTN and 19% showed co-prevalence of diabetes and hypertension (T2DM\*HTN).

The co-prevalence rate in Aligarh city (19%) is notably lower compared to other national studies: Gujarat (47%), Kerala (30%), and Tamil Nadu (61.4%)(Patel et al., 2013; Nair et al., 2018; Maniarasu & Muthunarayanan, 2017). International studies report even more variation in co-prevalence rates, with Nigeria ranging from 14% to 54.2%(Opeodu & Adeyemi, 2015; Unadike & Ohwovoriole, 2011). Japan at 62%(Yamakawa et al., 2019), Morocco and Iran at 70.4%(Berraho et al., 2012; Hashemizadeh, & Sarvelayati, 2013), and Northeast Ethiopia at 43.3%(Abejew et al., 2015). The mean age of patients with T2DM was 47.6 ± 1.0 years, while those with T2DM\*HTN had a higher mean age of 54.5 ± 1.1 years. A majority of the patients were female across both groups (T2DM: 60%; T2DM\*HTN: 76.7%).

**Table 1: Baseline Characteristics of the Patients (*N* = 320)**

|  |  |  |
| --- | --- | --- |
| Parameters | T2DM (*n* = 100) | T2DM\*HTN (*n* = 60) |
| Prevalence of diseases, *% (n)* | 31.3 (100) | 18.8 (60) |
| Gender, *% (n)* |  |  |
| Male: Female | 40.0 (40); 60.0 (60) | 23.3 (14): 76.7 (46) |
|  |  |  |
| Age (years), *M ± SE* |
| Overall | 47.6 ± 1.0 | 54.5 ± 1.1 |
| Male: Female | 49.8 ± 1.8; 46.1 ± 1.2 | 60.6 ± 1.97; 52.6 ± 1.19 |
|  |  |  |
| Mean BMI, (kg/m2) |
| Overall | 25.6 ± 0.5 | 27.5 ± 0.7 |
| Male: Female, % (*n*) | 24.7 ± 0.7; 26.2 ± 0.7 | 25.6 ± 0.7; 28 ± 0.8 |
|  |  |  |
| HbA1c% |
| Overall | 8.6 ± 0.1 | 8.2 ± 0.2 |
| Male: Female | 8.7 ± 0.3; 8.5 ± 0.2 | 7.7 ± 0.5; 8.3 ± 0.3 |
|  |  |  |
| SBP (mmHg), *M ± SE* |
| Overall | − | 136.5 ± 3.4 |
| Male: Female | − | 129.7 ± 7.4; 138.6 ± 3.9 |
|  | − |  |
| DBP (mmHg), *M ± SE* |
| Overall | − | 92 ± 2.6 |
| Male: Female | − | 96.7 ± 7.7; 90.5 ± 2.5 |
| *Note.* N: Number of sample, M: Mean; SE: Standard error of mean; %/n: percentage and number of the samples, figure in parentheses represents frequencies; HbA1c%; Glycosylated Hemoglobin; T2DM: Type 2 diabetes mellitus; T2DM\*HTN: Diabetic hypertensive; BP: Blood pressure; SBP: Systolic Blood Pressure; DBP: Diastolic blood pressure; BMI: Body mass index. |

The mean BMI was 25.6 ± 0.5 kg/m² for T2DM patients and 27.2 ± 0.4 kg/m² for T2DM\*HTN patients. The average HbA1c% levels were comparable between T2DM (8.6 ± 0.2%) and T2DM\*HTN (8.2 ± 0.1%) patients. Male and female T2DM patients had similar HbA1c% levels (*M*: 8.7 ± 0.3, F: 8.5 ± 0.2), while among T2DM\*HTN patients, females exhibited a slightly higher mean HbA1c% level compared to males (M: 7.7 ± 0.5, F: 8.3 ± 0.3). For patients with T2DM\*HTN, the average systolic blood pressure (SBP) was 136.5 ± 3.4 mmHg, and the diastolic blood pressure (DBP) averaged 92.0 ± 2.6 mmHg.

As shown in Table 2, among T2DM patients, the analysis of bitter gourd consumption frequency revealed notable trends in glycemic control. Among those who never included bitter gourd in their meals (*n* = 68), 58.8% exhibited unsatisfactory glycemic control (HbA1c ≥ 8), while nearly 41% demonstrated satisfactory or ideal glycemic control. For patients who consumed bitter gourd occasionally (*n* = 16), over 80% had unsatisfactory glycemic control, with only 18.8% achieving ideal control. Conversely, among those who regularly consumed bitter gourd (*n* = 12), approximately 60% fell within the satisfactory or ideal range of glycemic control. Notably, among patients who always included bitter gourd in their diet (*n* = 4), about 75% achieved ideal glycemic control. Fisher's exact test statistic of 16.72 (*p* = 0.004) and Somers’ *d* value (*d* = -0.115, *p* < 0.05) indicated a low but significant negative association between bitter gourd consumption and HbA1c levels in T2DM patients. In simpler terms, frequent consumption of bitter gourd is associated with a gradual reduction in HbA1c levels.

 Previous studies have highlighted the potential benefits of bitter melon (Momordica charantia) for managing metabolic conditions. For example, research has demonstrated that bitter melon contains bioactive compounds such as charantin, vicine, and polypeptide-p, which exhibit hypoglycemic effects through enhanced glucose uptake and insulin sensitivity. A study using alloxan-induced diabetic albino rats demonstrated the hypoglycemic effects of *Momordica charantia* methanolic extract, showing a dose-dependent reduction in blood glucose levels. This provides scientific support for its potential use as a natural remedy for managing diabetes (kumar et al., 2024). A review by **Hussain et al. (2022)** highlighted that bitter gourd is rich in nutrients and bioactive compounds like **momordicin I, II** and **cucurbitacin B**, which have antidiabetic effects. Its ability to regulate cholesterol, reduce fat accumulation, and improve antioxidant status supports both cardiovascular and glycemic health.

These findings align with the study’s observation of improved **HbA1c levels** in T2DM patients with frequent bitter gourd consumption. A review by Kwatra et al. (2016) emphasized that bitter melon has properties that can help lower blood glucose levels, supporting its potential as a dietary adjunct for diabetes management.The study supports that *Momordica charantia* has a dose-dependent hypoglycemic effect, aligning with the current finding that frequent bitter gourd consumption may help improve HbA1c levels in T2DM patients.

As observed in the T2DM\*HTN column, among patients who never included bitter gourd in their meals (n = 36), approximately 40% achieved ideal glycemic control, followed by 16.7% with satisfactory control and 45% with unsatisfactory glycemic control. Among those who consumed bitter gourd occasionally (*n* = 9), over 65% demonstrated unsatisfactory glycemic control, while 35% achieved healthy glycemic levels. For patients who consumed bitter gourd regularly (n = 10), nearly 70% successfully maintained their HbA1c% levels within the satisfactory or ideal range. Furthermore, ideal glycemic control was observed in all patients who consistently consumed bitter gourd. Despite these trends, the Fisher exact test statistic of 8.29 (p = 0.185) indicated that the association between bitter gourd consumption and HbA1c% levels in T2DM\*HTN patients was not statistically significant (p > 0.05). Although differences were noted, their lack of statistical significance underscores the need for further research with larger sample sizes and controlled settings to validate these findings.

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Table 2** |  |  |  |  |  |  |  |  |  |  |  |  |
| **Association between Frequency of Consuming bitter gourd and Control of HbA1c % Level among the Patients of T2DM and T2DM\*HTN** |
| Special Food | Frequency | T2DM  |   |   | T2DM\*HTN |   |
| Control of HbA1c % level | Total |  Fishers Exact Test |  | Control of HbA1c % level | Total | Fishers Exact Test |
| **< 7** | **≥7 - <8** | **≥ 8** |   | **< 7** | **≥7 - <8** | **≥ 8** |
| Bitter gourd | Never | 11.8 (8) | 29.4 (20) | 58.8 (40) | 68.0 (68) | \* Fisher Exact statistics= 16.72,  |  | 38.9 (14) | 16.7 (6) | 44.4 (16) | 60 (36) | Fisher Exact statistics = 8.29,  |
| Sometimes | 18.8 (3) | 0.0 (0) | 81.2 (13) | 16.0 (16) | *p* = .004, |  | 2 2.2 (2) | 11.1 (1) | 66.7 (6) | 15.0 (9) | *p* = .185  |
| Usually, | 33.3 (4) | 25.0 (3) | 41.7 (5) | 12.0 (12) | *d* = -.115  |  | 30.0 (3) | 40.0 (4) | 30.0 (3) | 16.7 (10) |  |
| Always | 75.0 (3) | 0.0 (0) | 25.0 (1) | 4.0 (4) |   |  | 60 (3) | 40.0 (2) | 0.0 (0) | 8.3 (5) |   |
| *Note.* Figures in parentheses indicates frequencies; \**p* < 0.05; *d* = Somers’d;  |
| Glycemic control: < 7: Ideal glycemic control, ≥7 -< 8: Satisfactory glycemic control, ≥ 8: Unsatisfactory glycemic control (ICMR, 2018). |

In the context of hypertension, bitter melon has also shown promise. Studies suggest that peptides derived from bitter melon inhibit angiotensin-converting enzyme (ACE), a key enzyme in blood pressure regulation. This dual effect on glucose metabolism and vascular function is particularly beneficial for individuals with comorbid diabetes and hypertension (Dahlquist et al., 2023; Hung et al., 2024). Moreover, a study by Wehash et al. (2012) indicated that bitter melon may exert effects on reducing capillary permeability, which could complement its antidiabetic properties. However, contrasting evidence exists. For instance, Yin et al. (2014) conducted a systematic review and meta-analysis and found no significant effect of bitter melon on HbA1c or fasting plasma glucose levels, suggesting variability in outcomes based on population, dosage, and study design.

**CONCLUSION**

In conclusion, while bitter gourd shows promise as a functional food with potential benefits for glycaemic and blood pressure control, the lack of statistically significant findings in this study underscores the need for robust, large-scale clinical trials to better understand its role in managing diabetic and diabetic hypertensives.

**Ethical Approval**

The study received ethical clearance from the Institutional Ethics Committee of Jawaharlal Nehru Medical College and Hospital, Aligarh Muslim University (Approval No. D. No. 367/FM, dated 14 March 2018).

**Consent**

As per international standards or university standards, Participants’ written consent has been collected and preserved by the author(s).

**ACKNOWLEDGEMENTS**

The authors acknowledge the contributions of the department of home science, faculty of agricultural sciences, Aligarh Muslim university, Aligarh, India.

**COMPETINGINTERESTS**

Authors have declared that no competing interests exist.

Disclaimer (Artificial intelligence)

Option 1:

Author(s) hereby declare that NO generative AI technologies such as Large Language Models (ChatGPT, COPILOT, etc.) and text-to-image generators have been used during the writing or editing of this manuscript.

Option 2:

Author(s) hereby declare that generative AI technologies such as Large Language Models, etc. have been used during the writing or editing of manuscripts. This explanation will include the name, version, model, and source of the generative AI technology and as well as all input prompts provided to the generative AI technology

Details of the AI usage are given below:

1.

2.

3.

**REFERENCES**

Abejew, A. A., Belay, A. Z., & Kerie, M. W. (2015). Diabetic complications among adult diabetic patients of a tertiary hospital in Northeast Ethiopia. Advances in Public Health, 2015.

Ahmad, N., Hasan, N., Ahmad, Z., Zishan, M., & Zohrameena, S. (2016). Momordica charantia: for traditional uses and pharmacological actions. Journal of Drug Delivery and Therapeutics, 6(2), 40-44.

American Diabetes Association. (2017). 2. Classification and diagnosis of diabetes. Diabetes care, 40(Supplement 1), S11-S24.

Anilakumar, K. R., Kumar, G. P., & Ilaiyaraja, N. (2015). Nutritional, pharmacological and medicinal properties of Momordica charantia. International Journal of Nutrition and Food Sciences, 4(1), 73-83.

Berraho, M., El Achhab, Y., Benslimane, A., Rhazi, K. E., Chikri, M., & Nejjari, C. (2012). Hypertension and type 2 diabetes: a cross-sectional study in Morocco (EPIDIAM Study). Pan African Medical Journal, 11(1).

Dahlquist, A., Jandali, D., Nauman, M. C., & Johnson, J. J. (2023). Clinical application of Momordica char-antia (Bitter Melon) for reducing blood sugar in type 2 diabetes melli-tus. International Journal of Nutrition-7 (4), 8-26.

De Boer, I. H., Bangalore, S., Benetos, A., Davis, A. M., Michos, E. D., Muntner, P., ... & Bakris, G. (2017). Diabetes and hypertension: a position statement by the American Diabetes Association. Diabetes care, 40(9), 1273-1284.

De Ferranti, S. D., De Boer, I. H., Fonseca, V., Fox, C. S., Golden, S. H., Lavie, C. J., ... & Zinman, B. (2014). Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association. Circulation, 130(13), 1110-1130.

Definition, W. H. O. (2006). Diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation. Geneva: World Health Organization, 3.

Fox, C. S., Golden, S. H., Anderson, C., Bray, G. A., Burke, L. E., De Boer, I. H., ... & Inzucchi, S. E. (2015). American Heart Association Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Clinical Cardiology, Council on Cardiovascular and Stroke Nursing, Council on Cardiovascular Surgery and Anesthesia, Council on Quality of Care and Outcomes Research; American Diabetes Association. Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the American Heart Association and the American.... Diabetes Care, 38(9), 1777-803.

Garrow, J.S. and Webster, J. 1985. Quetelets index (W/H2) as a measure of fatness. International Journal of Obesity 9: 147-53.

Gupta, M., Sharma, S., Gautam, A. K., & Bhadauria, R. (2011). Momordica charantia Linn.(Karela): Nature’s silent healer. International Journal of Pharmaceutical Sciences Review and Research, 11(1), 32-37.

Hashemizadeh, H., & Sarvelayati, D. (2013). Hypertension and type 2 diabetes: a cross-sectional study in hospitalized patients in Quchan, Iran. Iranian Journal of Diabetes and Obesity, 5(1), 21-26.

Hung, W. T., Sutopo, C. C. Y., Mahatmanto, T., Wu, M. L., & Hsu, J. L. (2024). Exploring the Antidiabetic and Antihypertensive Potential of Peptides Derived from Bitter Melon Seed Hydrolysate. Biomedicines, 12(11), 2452.

Hussain, R., Perveen, R., Murtaza, A., Huali, X., Manzoor, M. S., Younas, S., ... & Babur, M. N. (2022). Medicinal and healthpromoting properties of bitter gourd (Momordica charantia) and its extracts. J Pharm Res Int, 34, 66-76.

ICMR (2018). Guidelines for Management of Type 2 Diabetes. Indian Council of Medical Research, New Delhi.

Indian Consensus Group. (1996). Indian consensus for prevention of hypertension and coronary heart disease. A joint scientific statement of Indian Society of Hypertension and International College of Nutrition. J Nutr Environ Med, 6, 309-318.

International diabetes federation. IDF Diabetes Atlas, 8th edition, Brussels Belgium: international diabetes federation, 2017.

Kaur G. (2017). Diet cal: A tool for dietary assessment and planning; software version 8.: Profound Tech Solutions. Department of Dietetics, AIIMS, New Delhi, India.

Kumar, S., Shachi, K., & Dubey, N. K. (2024). Impact of Bitter Gourd (Momordica charantia) Hypoglycemic Formulation on Biochemical Parameters in Alloxan-induced Diabetic Albino Rats. Asian Journal of Research in Zoology, 7(4), 1–12. https://doi.org/10.9734/ajriz/2024/v7i4163

Kwatra, D., Dandawate, P., Padhye, S., & Anant, S. (2016). Bitter Melon as a Therapy for Diabetes, Inflammation, and Cancer: a Panacea?. Current Pharmacology Reports, 2(1), 34-44.

Longvah, T., Ananthan, R., Bhaskarachary, K., & Venkaiah, K. (2017). Indian Food Composition Tables. (T. Longvah, Ed.). Hyderabad, India: National Institute of Nutrition, Indian Council of Medical Research, Ministry of Health and Family Welfare, Government of India.

Maniarasu, K., & Muthunarayanan, L. (2017). Prevalence of certain chronic complications of diabetes among type 2 diabetic patients in rural population of Kancheepuram District, Tamil Nadu-a cross sectional study. International Journal of Medicine and Public Health, 7(1).

Nair, A., Jayakumari, C., Jabbar, P. K., Jayakumar, R. V., Raizada, N., Gopi, A., ... & Seena, T. P. (2018). Prevalence and Associations of Hypothyroidism in Indian Patients with Type 2 Diabetes Mellitus. Journal of thyroid research, 2018.

National Family Health Survey 2015-2016, Ministry of Health and Family Welfare (MoHFW)GovernmentofIndia.Availableat:http://rchiips.org/NFHS/pdf/NFHS4/India.pdf

NCD Risk Factor Collaboration. (2016). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4· 4 million participants. The Lancet, 387(10027), 1513-1530.

Opeodu, O. I., & Adeyemi, B. F. (2015). Prevalence of coexisting diabetes mellitus and hypertension among dental patients in a tertiary care hospital. Journal of the West African College of Surgeons, 5(3), 16.

Patel, M., Patel, I. M., Patel, Y. M., & Rathi, S. K. (2013). A hospital-based observational study of type 2 diabetic subjects from India. Indian J Clin Pract, 24, 141-148.

Paul A. James, MD; Suzanne Oparil, MD; Barry L. Carter, PharmD; William C. Cushman, MD; Cheryl Dennison-Himmelfarb, RN, ANP, PhD; Joel Handler, MD;Daniel T. Lackland, DrPH; Michael L. LeFevre, MD, MSPH; ThomasD. MacKenzie, MD, MSPH; Olugbenga Ogedegbe, MD, M. (2014). 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8), 1097(5), 507–520. https://doi.org/10.1001/jama.2013.284427

Petrie, J. R., Guzik, T. J., & Touyz, R. M. (2018). Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms. Canadian Journal of Cardiology, 34(5), 575-584.

Singh A, Masuku M. Sampling Techniques & Determination of Sample Size in Applied Statistics Research: an Overview. IjecmCoUk [Internet]. 2014;II(11):1–22. Available from: http://ijecm.co.uk/wp-content/uploads/2014/11/21131.pdf

Unadike, B. C., Eregie, A., & Ohwovoriole, A. E. (2011). Prevalence of hypertension amongst persons with diabetes mellitus in Benin City, Nigeria. Nigerian journal of clinical practice, 14(3), 300-302.

Wehash, F. E., Abpo-Ghanema, I. I., & Saleh, R. M. (2012). Some physiological effects of Momordica charantia and Trigonella foenum-graecum extracts in diabetic rats as compared with cidophage®. World Academy of Science, Engineering and Technology, 64, 1206-1214.

Who, E. C. (2004). Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet (London, England), 363(9403), 157.

World Health Organization, Public Health Agency of Canada, & Canada. Public Health Agency of Canada. (2005). Preventing chronic diseases: a vital investment. World Health Organization

World Health Organization. (2018). Noncommunicable diseases country profiles 2018. Geneva (CH): License CC BY-NC-SA 3.0 IGO2018.

Yamakawa, T., Sakamoto, R., Takahashi, K., Suzuki, J., Matuura‐Shinoda, M., Takahashi, M., ... & Kawata, T. (2019). Dietary survey in Japanese patients with type 2 diabetes and the influence of dietary carbohydrate on glycated hemoglobin: The Sleep and Food Registry in Kanagawa study. Journal of diabetes investigation, 10(2), 309-317.

Yin, R. V., Lee, N. C., Hirpara, H., & Phung, O. J. (2014). The effect of bitter melon (Mormordica charantia) in patients with diabetes mellitus: a systematic review and meta-analysis. Nutrition & diabetes, 4(12), e145.